ArticleExperimental hematology & oncology2026
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmunotherapy.
Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Follicular T cells in the ovarian cancer immune microenvironment: biological insights and translational implications.Frontiers in immunology · 2026Review
- Tertiary lymphoid structures in neoadjuvant and perioperative cancer immunotherapy: a review and proposed framework for biomarker interpretation and validation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe majority of patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoimmunotherapy (nCIT) failed to achieve pathologic complete response (pCR), had high risk of postoperative recurrence and lacked prognostic biomarkers. Tertiary lymphoid structures (TLS) are organized aggregates of immune cells and have the potential to regulate antitumor immune response. This study aimed to investigate the prognostic value and immune profile of TLS in non-pCR ESCC.
methodsWe first analyzed clinicopathological features, recurrence events, and survival outcomes according to TLS status. Subsequently, based on the single-cell sequencing data, we analyzed the differences in the infiltration level, functional status and interaction mode of immune cells based on TLS status. The expression pattern of signature genes and the spatial localization of key immune cell subsets were verified through bulk RNA sequencing and multiplex immunohistochemistry.
resultsThe TLS(+) group demonstrated a lower likelihood of postoperative recurrence and superior survival rates relative to the TLS(-) group. The key immune cell subsets responsive to immunotherapy were enriched in the TLS(+) group, and the immune cells in the TLS(+) group showed a functional state of high activation and low exhaustion. Multiplex immunohistochemistry and cell-cell communication analysis suggested that tumor reactive T cells were spatially colocalized with B cells and antigen presenting cells in TLS and exhibited high interaction potential. In the TLS(+) group, we also identified precursor exhausted T cells and long-lived plasma cells with tumor reactivity and matured affinity. The presence of TLS correlated with enhanced synergistic interaction, activation and maturation of immune cells, suggesting a potential role in shaping in situ antitumor immunity.
conclusionsTLS status was the independent predictor of postoperative recurrence in non-pCR ESCC. TLS status correlated with the composition, functional state, and interaction patterns of immune cells. Specialized immune niches existed in non-pCR ESCC with TLS, potentially contributing to antitumor immune responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.